Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non-small-Cell Lung Cancer Treated With Pembrolizumab.

Jemielita, Thomas; Li, Xiaoyun Nicole; Burke, Thomas; Liaw, Kai-Li; Zhou, Wei; Chen, Cong

Jemielita, Thomas; Li, Xiaoyun Nicole; Burke, Thomas; Liaw, Kai-Li; Zhou, Wei; Chen, Cong.

Affiliation

Jemielita T; Merck & Co Inc, Kenilworth, NJ.
Li XN; Merck & Co Inc, Kenilworth, NJ.
Burke T; Merck & Co Inc, Kenilworth, NJ.
Liaw KL; Merck & Co Inc, Kenilworth, NJ.
Zhou W; Merck & Co Inc, Kenilworth, NJ.
Chen C; Merck & Co Inc, Kenilworth, NJ.

JCO Clin Cancer Inform ; 5: 849-858, 2021 08.

Article in En | MEDLINE | ID: mdl-34415774

Subject(s)

Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Antibodies, Monoclonal, Humanized/therapeutic use; Carcinoma, Non-Small-Cell Lung/drug therapy; Humans; Lung Neoplasms/drug therapy; Time Factors

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: JCO Clin Cancer Inform Year: 2021 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google